Atopic dermatitis disease biomarkers strongly correlate with IL-13 levels, are regulated by IL-13, and are modulated by tralokinumab in vitro

Main Article Content

Stephan Weidinger
Maxim A.X. Tollenaere
Katharina Drerup
Thomas Litman
Hanne Norsgaard

Keywords

atopic dermatitis, tralokinumab, IL-13

Abstract

Abstract not available.

References

1. Weidinger S et al. Nat Rev Dis Primers. 2018;4:1.

2. Tsoi LC et al. J Invest Dermatol. 2019;139:1480–1489.

3. Purwar R et al. J Invest Dermatol. 2006;126:1043–1051.

4. Fukuda K et al. J Allergy Clin Immunol. 2003;111:520–526.

5. Matsumura S et al. J Dermatol Sci. 2015;78:215–223.

6. Kim BE et al. Clin Immunol. 2008;126:332–337.

7. Pellerin L et al. J Allergy Clin Immunol. 2013;131:1094–1102.

8. Berdyshev E et al. JCI Insight. 2018;3:pii 98006.

9. Popovic B et al. J Mol Biol. 2017;429:208–219.